Impax Laboratories (NASDAQ: IPXL ) Q2 2014 Earnings Call August 06, 2014 8:30 am ET Executives Mark Donohue - Vice President of Investor Relations and Corporate
Impax Laboratories ( IPXL +1.3% ) Q2 results : Revenues: $188.1M (+45.1%); Gross Profit: $109.8M (+86.4%); Operating Expenses
Impax Lab (NASDAQ: IPXL ): Q2 EPS of $0.60 beats by $0.22 . Revenue of $188.1M (+45.1% Y/Y) beats by $32.13M . Press Release Post your comment!
CHK , CLH , CMLS , CNP , CONE , CSTE , CTSH , DBD , DISH , DNR , DVN , DWSN , EE , ELOS , GEO , GOV , GWPH , HFC , HNT , INXN , IPXL , ITC , KELYA , LINC , LIOX , MDLZ , MEMP , MVIS , NAVB , NUS , PERI , PH , PKD , POWR , RDC , RL , ROC , SBGI , SE , SEP , SF
The FDA reinspected Impax Laboratories ' (NASDAQ: IPXL ) Hayward, California manufacturing facility from June 16 to July 31, 2014. In its Form 483, it cited seven observations
July 29 (Reuters) - Impax Laboratories Inc said the U.S. Food and Drug Administration issued "certain observations" after an inspection of the company's manufacturing plant in Taiwan.
(Reuters) - Shares of Impax Laboratories Inc fell as much as 10 percent on Tuesday, after U.S. health regulators denied approval to the company's Parkinson's drug and asked for a reinspection of its...
(Reuters) - Impax Laboratories Inc said it received a warning letter from U.S. health regulators on deficient sampling and testing of drugs at its Hayward, California-based plant, sending the...
competition until late 2011, thanks to several deals with Teva TEVA, Sandoz (a unit of Novartis NVS), Mylan MYL, and Impax IPXL . By paying the generic companies to delay competition, Medicis has lengthened the runway for Solodyn. The firm may have bought
stocks. Nearly one fourth of this fund's assets are in micro-cap stocks such as top-10 holdings TNS TNS, Impax Laboratories IPXL , and Omnicell OMCL, and its average market cap is less than $1 billion, as opposed to Mid Cap Growth's